J Kenneth Glass - Net Worth and Insider Trading
J Kenneth Glass Net Worth
The estimated net worth of J Kenneth Glass is at least $1 Million dollars as of 2024-04-19. J Kenneth Glass is the Director of FedEx Corp and owns about 5,000 shares of FedEx Corp (FDX) stock worth over $1 Million. J Kenneth Glass is also the Director of Oncternal Therapeutics Inc and owns about 178 shares of Oncternal Therapeutics Inc (ONCT) stock worth over $1,531. Details can be seen in J Kenneth Glass's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that J Kenneth Glass has not made any transactions after 2016-03-01 and currently still holds the listed stock(s).
Transaction Summary of J Kenneth Glass
J Kenneth Glass Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, J Kenneth Glass owns 3 companies in total, including Oncternal Therapeutics Inc (ONCT) , First Horizon Corp (FHN) , and FedEx Corp (FDX) .
Click here to see the complete history of J Kenneth Glass’s form 4 insider trades.
Insider Ownership Summary of J Kenneth Glass
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
ONCT | Oncternal Therapeutics Inc | 2016-03-01 | director |
FHN | First Horizon Corp | 2003-07-01 | director & President & CEO |
FDX | FedEx Corp | 2003-12-31 | director |
J Kenneth Glass Latest Holdings Summary
J Kenneth Glass currently owns a total of 2 stocks. Among these stocks, J Kenneth Glass owns 5,000 shares of FedEx Corp (FDX) as of December 31, 2003, with a value of $1 Million and a weighting of 99.88%. J Kenneth Glass also owns 178 shares of Oncternal Therapeutics Inc (ONCT) as of March 1, 2016, with a value of $1,531 and a weighting of 0.12%.
Latest Holdings of J Kenneth Glass
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
FDX | FedEx Corp | 2003-12-31 | 5,000 | 263.37 | 1,316,850 |
ONCT | Oncternal Therapeutics Inc | 2016-03-01 | 178 | 8.60 | 1,531 |
Holding Weightings of J Kenneth Glass
J Kenneth Glass Form 4 Trading Tracker
According to the SEC Form 4 filings, J Kenneth Glass has made a total of 0 transactions in FedEx Corp (FDX) over the past 5 years. The most-recent trade in FedEx Corp is the acquisition of 5,000 shares on December 31, 2003, which cost J Kenneth Glass around $341,700.
According to the SEC Form 4 filings, J Kenneth Glass has made a total of 0 transactions in Oncternal Therapeutics Inc (ONCT) over the past 5 years. The most-recent trade in Oncternal Therapeutics Inc is the acquisition of 31 shares on March 1, 2016, which cost J Kenneth Glass around $26,400.
Insider Trading History of J Kenneth Glass
- 1
J Kenneth Glass Trading Performance
GuruFocus tracks the stock performance after each of J Kenneth Glass's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by J Kenneth Glass is 15.41%. GuruFocus also compares J Kenneth Glass's trading performance to market benchmark return within the same time period. The performance of stocks bought by J Kenneth Glass within 3 months outperforms 9 times out of 17 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how J Kenneth Glass's insider trading performs compared to the benchmark.
Performance of J Kenneth Glass
Average Return
-10.45%
Outperforming Transactions
25%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 10.4 | 15.41 | 8.11 | -10.45 | -4.27 | -8.57 |
Relative Return to S&P 500(%) | 12.35 | 15.05 | 5 | -20.66 | -15.85 | -17.42 |
J Kenneth Glass Ownership Network
Ownership Network List of J Kenneth Glass
Ownership Network Relation of J Kenneth Glass
J Kenneth Glass Owned Company Details
What does Oncternal Therapeutics Inc do?
Who are the key executives at Oncternal Therapeutics Inc?
J Kenneth Glass is the director of Oncternal Therapeutics Inc. Other key executives at Oncternal Therapeutics Inc include director & Executive Chairman Robert James Wills , Chief Scientific Officer Gunnar F. Kaufmann , and Chief Medical Officer Salim Yazji .
Oncternal Therapeutics Inc (ONCT) Insider Trades Summary
Over the past 18 months, J Kenneth Glass made no insider transaction in Oncternal Therapeutics Inc (ONCT). Other recent insider transactions involving Oncternal Therapeutics Inc (ONCT) include a net purchase of 9,020 shares made by Robert James Wills , a net purchase of 150,000 shares made by James B Breitmeyer , and a net purchase of 30,000 shares made by Richard G Vincent .
In summary, during the past 3 months, insiders sold 980 shares of Oncternal Therapeutics Inc (ONCT) in total and bought 10,980 shares, with a net purchase of 10,000 shares. During the past 18 months, 980 shares of Oncternal Therapeutics Inc (ONCT) were sold and 23,880 shares were bought by its insiders, resulting in a net purchase of 22,900 shares.
Oncternal Therapeutics Inc (ONCT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Oncternal Therapeutics Inc Insider Transactions
J Kenneth Glass Mailing Address
Above is the net worth, insider trading, and ownership report for J Kenneth Glass. You might contact J Kenneth Glass via mailing address: 175 Toyota Plaza, 7th Floor, Memphis Tn 38103.